Physician profile
Joyce Chams
NPI 1114035110
$3,156.00
in general payments reported to CMS, 2019-2025
28 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $464 · 2021: $530 · 2022: $553 · 2023: $429 · 2024: $538 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,139 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,139.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.68 | 2019-2024 | Lo Loestrin Fe |
| Pfizer INC. | $409.18 | 2019-2024 | |
| Therapeuticsmd, INC. | $320.15 | 2019-2022 | |
| Astellas Pharma US INC | $240.04 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $186.69 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $179.38 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $178.07 | 2023-2024 | Myfembree |
| Hologic Sales and Service, LLC | $177.81 | 2019-2025 | Aptima, Novasure |
| Avion Pharmaceuticals | $162.53 | 2020-2023 | Balcoltra |
| Coopersurgical, INC. | $88.16 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $82.33 | 2019-2025 | |
| Exeltis, USA INC. | $80.20 | 2021-2024 | Slynd, Nuvessa |
| Exact Sciences Corporation | $79.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Minerva Surgical, INC | $49.73 | 2019-2023 | |
| Lupin INC. | $48.01 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $45.12 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Aspira Women'S Health INC | $42.26 | 2020-2024 | Ova1 |
| Scynexis, INC. | $41.81 | 2022 | |
| Medtronic, INC. | $40.79 | 2022 | |
| Agile Therapeutics, INC. | $24.03 | 2021 | |
| Becton, Dickinson and Company | $23.65 | 2023 | Bd Max System, Bd Max Instrument |
| Duchesnay USA Incorporated | $19.65 | 2019 | |
| Acessa Health INC. | $18.80 | 2019 | |
| Medline Industries LP | $18.68 | 2024 | Medline Industries, INC. |
| Shield Therapeutics INC | $17.44 | 2023 | Accrufer |
| Channel Medsystems, INC. | $17.03 | 2023 | |
| Amag Pharmaceuticals, INC. | $16.57 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Chams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.